Home

Clarus Lifesciences II, L.P.

CIK 1431443 · last filed 2018-09-19

Clarus Lifesciences II, L.P. is a corporate insider who has filed 6 SEC Form 4 insider transactions across 3 companies since 2013. The most recent filing, for NSTG, was dated Sep 19, 2018. Across all open-market trades the lifetime net is +$28.5M, making them a net buyer over the disclosed history. The firm reports its address in Cambridge, MA. 44 SEC filings were submitted jointly with Clarus Ventures II GP, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

6

Lifetime Open-Market Net

$28.55M

Filer Profile

Reported Address
101 MAIN STREET
SUITE 1210
CAMBRIDGE, MA 02142
Phone
(617) 949-2200
State of Incorporation
DE
Related Filers
Clarus Ventures II GP, L.P. — 44 joint filings, latest 2019-03-22
Clarus Ventures II, LLC — 43 joint filings, latest 2018-09-19
NICHOLAS GALAKATOS — 32 joint filings, latest 2017-10-17
DENNIS HENNER — 32 joint filings, latest 2017-10-17
ROBERT LIPTAK — 32 joint filings, latest 2017-10-17
KURT WHEELER — 32 joint filings, latest 2017-10-17
Nicholas Simon — 31 joint filings, latest 2017-10-17
MICHAEL STEINMETZ — 29 joint filings, latest 2016-02-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NanoString Technologies Inc (NSTG) Delisted 10%+ Owner 4,036,025 $0.11 $425.0K $18.38M 2 2018-09-19
TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted 10%+ Owner 2,445,030 — — -$3.39M 3 2016-02-10
Astria Therapeutics, Inc. (CATB) Delisted 10%+ Owner 458,748 $8.54 $3.92M $13.56M 1 2015-06-30

Recent Filings

6 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2018-09-19 NanoString Technologies Inc (NSTG) Delisted Mixed +229,755 -$861 EDGAR
2016-02-10 TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted Sell (S) −3,002,670 -$508.3K EDGAR
2016-02-05 TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted Sell (S) −12,739,410 -$2.24M EDGAR
2016-02-02 TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted Sell (S) −3,322,188 -$645.4K EDGAR
2015-06-30 Astria Therapeutics, Inc. (CATB) Delisted Mixed +8,257,464 $13.56M EDGAR
2013-07-01 NanoString Technologies Inc (NSTG) Delisted Mixed +11,878,320 $22.50M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.